[Carbocalcitonin, a new synthetic calcitonin: clinical evaluation].
Fifteen patients suffering from osteoporosis of different aetiology and receiving long-term carbocalcitonin treatment were studied in order to evaluate the tolerance of the drug. Only one of these patients, with intolerance of any type of calcitonin, was obliged to discontinue the treatment, tolerance being excellent in all the others. Blood-chemistry tests, performed at various intervals, revealed no significant changes. Though not part of the specific aim of the study, antalgic efficacy tests yielded excellent results.